{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-000571","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2024-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.121403+00:00","generated_at":"2026-06-07T04:43:31.974836+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Entrada Therapeutics promotes COO Nathan Dowden to President, effective Jan 1, 2024","bullets":["Nathan J. Dowden promoted to President, retains COO role; Dipal Doshi continues as CEO.","Salary increased to $480,000/year; target bonus raised to 45%.","Granted 60,000 RSUs vesting 50% on 2nd anniversary and 50% on 3rd anniversary.","Dowden has served as COO since Nov 2019 and has 30 years healthcare sector experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-000571","json":"https://secwatch.observer/filing/0001104659-24-000571.json","markdown":"https://secwatch.observer/filing/0001104659-24-000571.md","text":"https://secwatch.observer/filing/0001104659-24-000571.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000110465924000571/0001104659-24-000571-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000110465924000571/tm241489d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:43:31.974836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f1b4f2dba7","claim":"Nathan J. Dowden was appointed as President and Chief Operating Officer at Entrada Therapeutics, Inc..","evidence_excerpt":"appointed Nathan J. Dowden, the Company’s Chief Operating Officer, to serve as the Company’s President, effective as of January 1, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465924000571/0001104659-24-000571-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}